NIR178

DRUG6 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Carcinoma, Renal CellColorectal Cancer Microsatellite Stable (MSS)DLBCL, Diffused Large B Cell LymphomaDifferent types of advanced cancerHead and Neck CancerMSS, Microsatellite Stable Colon CancerMelanomaMetastatic Castration Resistant Prostate Cancer (mCRPC)

Early Phase 1

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

TerminatedNCT04237649

Novartis PharmaceuticalsSolid Tumors

Start: 2020-02-20End: 2023-09-15Updated: 2025-05-18

Phase 1

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

TerminatedNCT03549000

Novartis PharmaceuticalsColorectal Cancer Microsatellite Stable (MSS), Metastatic Castration Resistant Prostate Cancer (mCRPC), Non-small Cell Lung Cancer (NSCLC) +4

Start: 2018-07-18End: 2022-10-17Updated: 2024-12-13

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

TerminatedNCT03742349

Novartis PharmaceuticalsTriple Negative Breast Cancer (TNBC)

Start: 2019-01-31End: 2023-02-06Updated: 2025-05-18

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

TerminatedNCT04895748

Novartis PharmaceuticalsCarcinoma, Renal Cell

Start: 2021-11-30End: 2026-02-13Updated: 2026-03-03

An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments

Active, not recruitingCTIS2023-508841-42-00

Novartis Pharma AGDifferent types of advanced cancer

Start: 2019-10-30Target: 75Updated: 2025-10-28

Phase 2

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

TerminatedNCT03207867

Novartis PharmaceuticalsDLBCL, Diffused Large B Cell Lymphoma, Head and Neck Cancer, mCRPC, Metastatic Castration Resistant Prostate Cancer +7

Start: 2017-08-28End: 2023-02-14Updated: 2024-10-09

Related Papers

Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.

Journal of Clinical Oncology2024-06-017 citations

Abstract B114: A Phase 1/1b study of KAZ954 alone and in combination with spartalizumab (PDR001) and taminadenant (NIR178) in patients with advanced gastrointestinal malignancies

Molecular Cancer Therapeutics2023-12-01

Abstract CT503: A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies

Cancer Research2022-06-156 citations